Mustang Bio and City of Hope Announce First Patient Dosed in Phase 1 Clinical Trial of MB-101 (IL13Rα2-specific CAR T cells) to Treat Leptomeningeal Brain Tumors

NEXT STORY
Sarepta Therapeutics’ Investigational Gene Therapy for the Treatment of Duchenne Muscular Dystrophy, SRP-9001, Demonstrates Robust Expression and Consistent Safety Profile Using Sarepta’s Commercial Process Material
PREV STORY
Telehealth Market Size 2021 | Is Projected to Reach USD 559.52 Billion by 2027 with a CAGR of 25.2%
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Rhythm Pharmaceuticals Announces Late-breaking Data from Phase 3 Trials of Setmelanotide in POMC and LEPR Deficiency Obesities at ObesityWeek 2019

author_avatar
NASDAQ Market News

Karyopharm Announces Agreement for Biogen to Acquire KPT-350 for the Treatment of Neurological and Neurodegenerative Conditions

− Biogen Brings Expertise in Development and Commercialization of Products for Neurological and Neurodegenerative ...

author_avatar
NASDAQ Market News

Cesca Therapeutics to Present at the Inaugural Cell and Gene Exchange 2017

RANCHO CORDOVA, Calif., May 18, 2017 (GLOBE NEWSWIRE) -- Cesca Therapeutics Inc. (NASDAQ:KOOL), a ...

author_avatar
NASDAQ Market News